EGAGenomicsCancer Genomicshttps://ega-archive.org/studies/EGAS00001007308EGAEGA study EGAS00001007308Cell-free DNA sequencing data of healthy control, atrophic gastritis, and gastric cancer patients’ bloodEGArestrictedd230, Sequence Determination, Neoplasms, dTAFII250, EfW1, Stomach Neoplasms, prevention, malignant fundus of stomach neoplasm, NEOPL STOMACH, dmTAF[[II]]230, Gastritides, Ca fundus - stomach, Atrophic Gastritides, stomach neoplasm, dmTAF1, malignant neoplasm of fundus of stomach, Familial Diffuse, Taf230, Gastritis, atrophic Gastritides, malignant tumor of fundus of stomach, Analysis, tumor of the stomach, gastric fundus cancer, gastric neoplasm, prevention and control, stomach tumor, TAF250, Taf200, dTAF[[II]]250, TFIID TAF250, reference sample, Analyses, cel, Determination, cell, stomach tumour, Taf1p, Gastric Cancer, Sequence Determinations, free, Sequencing, preventive measures, malignant neoplasm of body of stomach, dTAF250, DNA Sequence Analysis, gastric cancer, malignant tumour of fundus of stomach, Cancer of Stomach, Clients, Cancer of the Stomach, TAF, Ca body - stomach, Controlled, Sequence Analyses, Cancer, tumour of stomach, Controlling, dTAF[[II]]230, TAF[[II]]250, preventive therapy, Stomach Neoplasm, atrophic gastritis, GASC, TAF200, l(3)84Ab, BG:DS00004.13, neoplasm of the stomach, TAFII-250, TAF250/230, fundus of stomach cancer, cancer of fundus of stomach, Client, Cell, Gastric cancer, gastric tumor, STOMACH NEOPL, Determinations, dTAF230, Stomach Cancers, TAFII250, p230, DNA Sequencing, DNA Sequence Determinations, Neoplasm, TAF[[II]]250/230, TFIID, Atrophic Gastritis, Gastric Neoplasms, DNA Sequence, Atrophic, Gastric, DNA sequencing, atrophic, Stomach Cancer, Taf[[II]]250, TAF[[II]]230, gastric tumour, gastric atrophy, stomach neoplasm (disease), prophylaxis, whole blood., Gastric Cancers, TAF[II]250, Cancers, CG17603, TAF[[II]], Gastric Neoplasm, DNA Sequence Determination, Stomach, DmelCG17603, DNA Sequence Analyses, Taf250, Patient, control, SR3-5, neoplasm of stomach, NEOPL GASTRIC, tumor of stomach, chronic atrophic gastritis, DNA, tumour of the stomach, TAF230, ca greater curvature of stomach, TAF1, GASTRIC NEOPLBiological Markers, Viral Marker, Surrogate Endpoints, Laboratory, Sequence Determination, Biochemical, Endpoint, Profiles, Serum, Stomach Neoplasms, malignant fundus of stomach neoplasm, prevention, NEOPL STOMACH, dmTAF[[II]]230, Laboratory Markers, Gastritides, Atrophic Gastritides, diseases, malignant neoplasm of fundus of stomach, Familial Diffuse, Biological, Gastritis, atrophic Gastritides, diseases and disorders, Analysis, tumor of the stomach, gastric fundus cancer, gastric neoplasm, Fs(3)Hor, prevention and control, thymus nucleic acid, human disease, DmelCG2684, TFIID TAF250, reference sample, Analyses, cel, Determination, NTef2, Sequence Determinations, free, malignant neoplasm of body of stomach, preventive measures, DNA Sequence Analysis, Immune, Markers, malignant tumour of fundus of stomach, Viral Markers, Genetic Profiles, Allele, Homo sapiens disease, Double-Stranded DNA, Genotype Profiles, deoxyribonucleic acids, DNAn, Cancer of the Stomach, Ca body - stomach, dTAF[[II]]230, preventive therapy, Viral, Surrogate Endpoint, GASC, TAF200, Biochemical Markers, Double-Stranded, neoplasm of the stomach, TAFII-250, TAF250/230, Biologic Marker, STOMACH NEOPL, Determinations, Fs(3)Sz11, (Deoxyribonucleotide)n+m, TAFII250, Genotype Profile, Genotype, Marker, DNA Sequence Determinations, Diseases, Atrophic Gastritis, Gastric Neoplasms, DNA Sequence, desoxyribose nucleic acid, DNA sequencing, Stomach Cancer, gastric tumour, End Points, stomach neoplasm (disease), gastric atrophy, Immunologic, Laboratory Marker, CG17603, TAF[[II]], early, Stomach, disease, Taf250, Biochemical Marker, SR3-5, neoplasm of stomach, Horka, ds DNA, tumor of stomach, CG2684, chronic atrophic gastritis, Fs(3)Horka, medical condition., DNA, TAF230, ca greater curvature of stomach, other disease, Allelomorphs, d230, DNS, (Deoxyribonucleotide)n, Clinical Markers, Clinical Marker, Neoplasms, dTAFII250, EfW1, Deoxyribonucleic acids, Surrogate End Points, Surrogate Markers, Ca fundus - stomach, Deoxyribonucleic Acid, stomach neoplasm, dmTAF1, Taf230, disease or disorder, malignant tumor of fundus of stomach, DmF2, stomach tumor, TAF250, lod, study, Biomarker, Taf200, dTAF[[II]]250, Genetic, Clinical, cell, Profile, Biological Marker, stomach tumour, Double Stranded, Taf1p, Deoxyribonucleic acid, Gastric Cancer, Sequencing, Allelomorph, non-neoplastic, dTAF250, gastric cancer, Immunologic Markers, Cancer of Stomach, disorder, (Deoxyribonucleotide)m, TAF, Immunologic Marker, Biologic, Controlled, Sequence Analyses, Cancer, tumour of stomach, Controlling, TAF[[II]]250, Stomach Neoplasm, atrophic gastritis, DNAn+1, Serum Markers, disorders, End Point, l(3)84Ab, BG:DS00004.13, medical condition, fundus of stomach cancer, cancer of fundus of stomach, Cell, Gastric cancer, gastric tumor, Immune Marker, dTAF230, Stomach Cancers, Surrogate End Point, p230, DNA Sequencing, Neoplasm, TAF[[II]]250/230, TFIID, condition, ds-DNA, Gastric, Atrophic, atrophic, Biologic Markers, Taf[[II]]250, Serum Marker, TAF[[II]]230, Surrogate, prophylaxis, Endpoints, Gastric Cancers, TAF[II]250, Cancers, Lds, Gastric Neoplasm, Surrogate Marker, DNA Sequence Determination, DmelCG17603, DNA Sequence Analyses, control, NEOPL GASTRIC, Desoxyribonukleinsaeure, tumour of the stomach, TAF1, GASTRIC NEOPL, Immune MarkersfalseCell-free DNA sequencing data of healthy control, atrophic gastritis, and gastric cancer patients’ bloodIn this study, cell-free DNA sequencing is performed to obtain a personalized genetic profile of cell-free DNA during the course of gastric cancer. The study involves control, premalignant (atrophic gastritis), and malignant gastric cancer cases. Detected variant alleles and determined fractions during the course of a disease, will show the possible application of cfDNA as a minimally-invasive biomarker for not only early GC diagnostics but also for GC disease state monitoring.2023-07-18 15:50:42EGAS000010073089606EGAD00001011153EGAC00001003304